Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.10). During the same period last year, the firm earned ($0.31) EPS. On average, analysts expect Mineralys Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Price Performance

NASDAQ MLYS traded up $0.03 during trading hours on Tuesday, hitting $13.53. 104,701 shares of the company's stock traded hands, compared to its average volume of 172,362. The company has a market capitalization of $672.85 million, a PE ratio of -4.98 and a beta of 1.71. The firm's 50-day moving average is $12.75 and its 200-day moving average is $12.54. Mineralys Therapeutics has a 52-week low of $5.85 and a 52-week high of $16.91.

Insider Activity at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now owns 236,854 shares in the company, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the sale, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jon Congleton sold 15,271 shares of the firm's stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the sale, the chief executive officer now owns 895,941 shares of the company's stock, valued at $12,113,122.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 33.24% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a report on Thursday, October 31st.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.